The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Opportunities and impediments of human pluripotent stem cell-derived islets in the treatment of diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ability to generate large numbers of insulin-producing cells from human pluripotent SC can restore normal endogenous insulin production and effectively manage diabetes in both animal models4,5 and human patients6–10.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [7]
In the citing paper
“generating SC-islets from a patient’s own iPSCs could potentially enable autologous islet cell transplantation without need for chronic immunosuppression, at least in non-autoimmune diabetes populations7.”
From Scale up manufacturing approach for production of human induced pluripotent stem cell-derived islets using Vertical Wheel® bioreactors (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Laurent, L. C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., Lynch, C., Harness, J. V., Lee, S., Barrero, M. J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2010.12.003 · Cited by 890
Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0016-3 · Cited by 758
Vegas, A. J., Veiseh, O., Gürtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., Doloff, J. C., Li, J., Chen, M., Olejnik, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4030 · Cited by 710
Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.003 · Cited by 584
Rezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582
Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells
Zhou, W., & Freed, C. R. (2009) · Stem Cells · doi:10.1002/stem.201 · Cited by 538
Nair, G. G., Liu, J. S., Russ, H. A., Tran, S., Saxton, M. S., Chen, R., Juang, C., Li, M.-L., Nguyen, V. Q., Giacometti, S., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0271-4 · Cited by 472
Balboa, D., Barsby, T., Lithovius, V., Saarimäki-Vire, J., Omar-Hmeadi, M., Dyachok, O., Montaser, H., Lund, P.-E., Yang, M., Ibrahim, H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01219-z · Cited by 433
Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells
Velazco-Cruz, L., Song, J., Maxwell, K. G., Goedegebuure, M. M., Augsornworawat, P., Hogrebe, N. J., & Millman, J. R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.012 · Cited by 399
Research works printed but not linked: 153
- Bommer, 2018, Global economic burden of diabetes in adults: projections from 2015 to 2030, Diabetes Care, 41, 963, 10.2337/dc17-1962 · DOI · Paper page
- Soumya D, 2011, Late stage complications of diabetes and insulin resistance, J Diabetes Metabol, 9
- Latres, 2019, Navigating two roads to glucose normalization in diabetes: automated insulin delivery devices and cell therapy, Cell Metabol, 29, 545, 10.1016/j.cmet.2019.02.007 · DOI
- Marfil-Garza, 2022, Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada, Lancet Diabetes Endocrinol., 10, 519, 10.1016/S2213-8587(22)00114-0 · DOI · Paper page
- Nair, 2020, Emerging routes to the generation of functional beta-cells for diabetes mellitus cell therapy, Nat Rev Endocrinol, 16, 506, 10.1038/s41574-020-0375-3 · DOI · Paper page
- Kerper, 2021, Pancreatic beta-cell development and regeneration, Cold Spring Harbor Perspect Biol
- Hussain, 2004, Stem-cell therapy for diabetes mellitus, Lancet, 364, 203, 10.1016/S0140-6736(04)16635-X · DOI
- Verhoeff, 2021, Inducible pluripotent stem cells as a potential cure for diabetes, Cells, 10, 10.3390/cells10020278 · DOI
- Rezania, 2014, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells, Nat Biotechnol, 32, 1121, 10.1038/nbt.3033 · DOI · Paper page
- Millman, 2017, Autologous pluripotent stem cell-derived beta-like cells for diabetes cellular therapy, Diabetes, 66, 1111, 10.2337/db16-1406 · DOI
- D'Amour, 2006, Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat Biotechnol, 24, 1392, 10.1038/nbt1259 · DOI · Paper page
- Pagliuca, 2014, Generation of functional human pancreatic beta cells in vitro, Cell, 159, 428, 10.1016/j.cell.2014.09.040 · DOI · Paper page
- James Shapiro, 2021, Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device, Cell Rep Med, 2
- Velazco-Cruz, 2020, Advances toward engineering functionally mature human pluripotent stem cell-derived beta cells, Front Bioeng Biotechnol, 8, 786, 10.3389/fbioe.2020.00786 · DOI
- Melton, 2019, Advancing progress in stem cells and biomedicine: 2018-2019 Year in review, Stem Cell Rep, 12, 1179, 10.1016/j.stemcr.2019.05.019 · doi:10.1016/j.stemcr.2019.05.019
- Aghazadeh, 2021, View ORCID ProfileSara S. Nunes, M. Cristina Nostro. GP2-enriched pancreatic progenitors give rise to functional beta cells in vivo and eliminate the risk of teratoma formation, bioRxiv, 5
- Bruin, 2014, Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells, Stem Cell Res, 12, 194, 10.1016/j.scr.2013.10.003 · DOI · Paper page
- Jensen, 2021, Characterization of the nonendocrine cell populations in human embryonic stem cell-derived (hESC) islet-like clusters posttransplantation, Toxicol Pathol, 1926233211036395
- Martin, 1981, Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells, Proc Natl Acad Sci U S A, 78, 7634, 10.1073/pnas.78.12.7634 · DOI · Paper page
- Evans, 1981, Establishment in culture of pluripotential cells from mouse embryos, Nature, 292, 154, 10.1038/292154a0 · DOI · Paper page
- Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 · DOI · Paper page
- Liu, 2020, Advances in pluripotent stem cells: history, mechanisms, technologies, and applications, Stem Cell Rev Rep, 16, 3, 10.1007/s12015-019-09935-x · DOI · Paper page
- Thomson, 1998, Embryonic stem cell lines derived from human blastocysts, Science, 282, 1145, 10.1126/science.282.5391.1145 · DOI · Paper page
- Odorico, 2001, Multilineage differentiation from human embryonic stem cell lines, Stem Cell, 19, 193, 10.1634/stemcells.19-3-193 · DOI · Paper page
- Caulfield, 2007, Informed consent in embryonic stem cell research: are we following basic principles?, CMAJ (Can Med Assoc J), 176, 1722, 10.1503/cmaj.061675 · doi:10.1503/cmaj.061675
- Zarzeczny, 2009, iPS cells: mapping the policy issues, Cell, 139, 1032, 10.1016/j.cell.2009.11.039 · DOI
- Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Malik, 2013, A review of the methods for human iPSC derivation, Methods Mol Biol, 997, 23, 10.1007/978-1-62703-348-0_3 · DOI · Paper page
- Sutherland, 1984, Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes, Trans Assoc Am Phys, 97, 80
- Sutherland, 1989, Recurrence of disease in pancreas transplants, Diabetes, 38, 85, 10.2337/diab.38.1.S85 · DOI · Paper page
- Liang, 2013, Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective, Cell Res, 23, 49, 10.1038/cr.2012.175 · DOI · Paper page
- Nichols, 2009, Naive and primed pluripotent states, Cell Stem Cell, 4, 487, 10.1016/j.stem.2009.05.015 · DOI · Paper page
- Takashima, 2014, Resetting transcription factor control circuitry toward ground-state pluripotency in human, Cell, 158, 1254, 10.1016/j.cell.2014.08.029 · DOI · Paper page
- Gu, 2016, Glycolytic metabolism plays a functional role in regulating human pluripotent stem cell state, Cell Stem Cell, 19, 476, 10.1016/j.stem.2016.08.008 · DOI · Paper page
- Qin, 2016, YAP induces human naive pluripotency, Cell Rep, 14, 2301, 10.1016/j.celrep.2016.02.036 · DOI · Paper page
- Tesar, 2016, Snapshots of pluripotency, Stem Cell Rep, 6, 163, 10.1016/j.stemcr.2015.12.011 · doi:10.1016/j.stemcr.2015.12.011
- Ying, 2008, The ground state of embryonic stem cell self-renewal, Nature, 453, 519, 10.1038/nature06968 · DOI · Paper page
- Davidson, 2015, The pluripotent state in mouse and human, Development, 142, 3090, 10.1242/dev.116061 · DOI
- Alexandrova, 2016, Selection and dynamics of embryonic stem cell integration into early mouse embryos, Development, 143, 24
- Chan, 2013, Induction of a human pluripotent state with distinct regulatory circuitry that resembles preimplantation epiblast, Cell Stem Cell, 13, 663, 10.1016/j.stem.2013.11.015 · DOI · Paper page
- Gafni, 2013, Derivation of novel human ground state naive pluripotent stem cells, Nature, 504, 282, 10.1038/nature12745 · DOI · Paper page
- Theunissen, 2014, Systematic identification of culture conditions for induction and maintenance of naive human pluripotency, Cell Stem Cell, 15, 471, 10.1016/j.stem.2014.07.002 · DOI · Paper page
- Irie, 2015, SOX17 is a critical specifier of human primordial germ cell fate, Cell, 160, 253, 10.1016/j.cell.2014.12.013 · DOI · Paper page
- Theunissen, 2016, Molecular criteria for defining the naive human pluripotent state, Cell Stem Cell, 19, 502, 10.1016/j.stem.2016.06.011 · DOI · Paper page
- Kiyokawa, 2020, Drug-induced naïve iPS cells exhibit better performance than primed iPS cells with respect to the ability to differentiate into pancreatic β-cell lineage, J Clin Med, 9, 10.3390/jcm9092838 · DOI
- Mayshar, 2010, Identification and classification of chromosomal aberrations in human induced pluripotent stem cells, Cell Stem Cell, 7, 521, 10.1016/j.stem.2010.07.017 · DOI · Paper page
- Hussein, 2011, Copy number variation and selection during reprogramming to pluripotency, Nature, 471, 58, 10.1038/nature09871 · DOI · Paper page
- Doss, 2019, Current challenges of iPSC-based disease modeling and therapeutic implications, Cells, 8, 10.3390/cells8050403 · DOI · Paper page
- Liu, 2017, The immunogenicity and immune tolerance of pluripotent stem cell derivatives, Front Immunol, 8, 645, 10.3389/fimmu.2017.00645 · DOI · Paper page
- Rouhani, 2016, Mutational history of a human cell lineage from somatic to induced pluripotent stem cells, PLoS Genet, 12, 10.1371/journal.pgen.1005932 · DOI
- Yamanaka, 2012, Induced pluripotent stem cells: past, present, and future, Cell Stem Cell, 10, 678, 10.1016/j.stem.2012.05.005 · DOI · Paper page
- Zhao, 2009, iPS cells produce viable mice through tetraploid complementation, Nature, 461, 86, 10.1038/nature08267 · DOI · Paper page
- Mikkelsen, 2008, Dissecting direct reprogramming through integrative genomic analysis, Nature, 454, 49, 10.1038/nature07056 · DOI · Paper page
- Chin, 2009, Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures, Cell Stem Cell, 5, 111, 10.1016/j.stem.2009.06.008 · DOI · Paper page
- Ghosh, 2010, Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells, PLoS One, 5, 10.1371/journal.pone.0008975 · DOI · Paper page
- Deng, 2009, Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming, Nat Biotechnol, 27, 353, 10.1038/nbt.1530 · DOI · Paper page
- Doi, 2009, Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts, Nat Genet, 41, 1350, 10.1038/ng.471 · DOI · Paper page
- Lister, 2011, Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells, Nature, 471, 68, 10.1038/nature09798 · DOI · Paper page
- Kim, 2011, Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells, Nat Biotechnol, 29, 1117, 10.1038/nbt.2052 · DOI · Paper page
- Ohi, 2011, Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells, Nat Cell Biol, 13, 541, 10.1038/ncb2239 · DOI · Paper page
- Guenther, 2010, Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells, Cell Stem Cell, 7, 249, 10.1016/j.stem.2010.06.015 · DOI · Paper page
- Newman, 2010, Lab-specific gene expression signatures in pluripotent stem cells, Cell Stem Cell, 7, 258, 10.1016/j.stem.2010.06.016 · DOI · Paper page
- Zhao, 2011, Immunogenicity of induced pluripotent stem cells, Nature, 474, 212, 10.1038/nature10135 · DOI · Paper page
- Deuse, 2019, De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans, Nat Biotechnol, 37, 1137, 10.1038/s41587-019-0227-7 · DOI
- Araki, 2013, Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells, Nature, 494, 100, 10.1038/nature11807 · DOI · Paper page
- Kaneko, 2013, To be immunogenic, or not to be: that's the iPSC question, Cell Stem Cell, 12, 385, 10.1016/j.stem.2013.03.008 · DOI
- Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat Biotechnol, 24, 687, 10.1038/nbt1216 · DOI · Paper page
- Mandai, 2017, Autologous induced stem-cell-derived retinal cells for macular degeneration, N Engl J Med, 376, 1038, 10.1056/NEJMoa1608368 · DOI · Paper page
- Li, 2016, Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain, Proc Natl Acad Sci U S A, 113, 6544, 10.1073/pnas.1605245113 · DOI · Paper page
- Meissner, 2008, Genome-scale DNA methylation maps of pluripotent and differentiated cells, Nature, 454, 766, 10.1038/nature07107 · DOI · Paper page
- Bhutani, 2010, Reprogramming towards pluripotency requires AID-dependent DNA demethylation, Nature, 463, 1042, 10.1038/nature08752 · DOI · Paper page
- Ban, 2011, Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors, Proc Natl Acad Sci U S A, 108, 14234, 10.1073/pnas.1103509108 · DOI · Paper page
- Sullivan, 2018, Quality control guidelines for clinical-grade human induced pluripotent stem cell lines, Regen Med, 13, 859, 10.2217/rme-2018-0095 · DOI · Paper page
- Nießing, 2021, Techno-economic analysis of automated iPSC production, Processes, 9, 240, 10.3390/pr9020240 · DOI
- Daniszewski, 2018, Automated cell culture systems and their applications to human pluripotent stem cell studies, SLAS Technol, 23, 315, 10.1177/2472630317712220 · DOI
- Rohani, 2020, Stirred suspension bioreactors maintain naive pluripotency of human pluripotent stem cells, Commun Biol, 3, 492, 10.1038/s42003-020-01218-3 · DOI
- Borys, B. S. et al. Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors. Stem Cell Res Ther 12, 55, doi:10.1186/s13287-020-02109-4(2021). · DOI
- Veres, 2019, Charting cellular identity during human in vitro beta-cell differentiation, Nature, 569, 368, 10.1038/s41586-019-1168-5 · DOI · Paper page
- Hogrebe, 2020, Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells, Nat Biotechnol, 38, 460, 10.1038/s41587-020-0430-6 · DOI · Paper page
- Velazco-Cruz, 2020, SIX2 regulates human beta cell differentiation from stem cells and functional maturation in vitro, Cell Rep, 31, 10.1016/j.celrep.2020.107687 · DOI
- Peterson, 2020, A method for the generation of human stem cell-derived alpha cells, Nat Commun, 11, 2241, 10.1038/s41467-020-16049-3 · DOI
- Sui, 2018, Pancreatic beta cell differentiation from human pluripotent stem cells, Curr Protoc Hum Genet, 99, e68, 10.1002/cphg.68 · DOI · Paper page
- Sui, 2021, Reduced replication fork speed promotes pancreatic endocrine differentiation and controls graft size, JCI Insight, 6, 10.1172/jci.insight.141553 · DOI · Paper page
- Stock, 2020, Conformal coating of stem cell-derived islets for β cell replacement in type 1 diabetes, Stem Cell Rep, 14, 91, 10.1016/j.stemcr.2019.11.004 · DOI · Paper page
- Yamanaka, 2020, Pluripotent stem cell-based cell therapy-promise and challenges, Cell Stem Cell, 27, 523, 10.1016/j.stem.2020.09.014 · DOI · Paper page
- Chung, 2006, Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation, J Neurochem, 97, 1467, 10.1111/j.1471-4159.2006.03841.x · DOI
- Huang, 2020, Signaling molecules regulating pancreatic endocrine development from pluripotent stem cell differentiation, Int J Mol Sci, 21, 10.3390/ijms21165867 · DOI
- Liu, 2020, Chromosomal aberration arises during somatic reprogramming to pluripotent stem cells, Cell Div, 15, 12, 10.1186/s13008-020-00068-z · DOI
- Okita, 2007, Generation of germline-competent induced pluripotent stem cells, Nature, 448, 313, 10.1038/nature05934 · DOI · Paper page
- Stadtfeld, 2008, Induced pluripotent stem cells generated without viral integration, Science, 322, 945, 10.1126/science.1162494 · DOI · Paper page
- Tokusumi, 2002, Recombinant Sendai viruses expressing different levels of a foreign reporter gene, Virus Res, 86, 33, 10.1016/S0168-1702(02)00047-3 · DOI
- Kroon, 2008, Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo, Nat Biotechnol, 26, 443, 10.1038/nbt1393 · DOI · Paper page
- Dadheech, 2019, Human induced pluripotent stem cells in the curative treatment of diabetes and potential impediments ahead, Adv Exp Med Biol, 1144, 25, 10.1007/5584_2018_305 · DOI
- Madrid, 2021, Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges, Curr Protoc, 1, e88, 10.1002/cpz1.88 · DOI
- Borys, 2020, Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors, Stem Cells Transl Med, 9, 1036, 10.1002/sctm.19-0406 · DOI · Paper page
- Huurman, 2008, Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation, PLoS One, 3, e2435, 10.1371/journal.pone.0002435 · DOI · Paper page
- Jaeger, 1997, Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts, Diabetes, 46, 1907, 10.2337/diab.46.11.1907 · DOI
- Piemonti, 2013, Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes, Diabetes, 62, 1656, 10.2337/db12-1258 · DOI
- Zhao, 2015, Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells, Cell Stem Cell, 17, 353, 10.1016/j.stem.2015.07.021 · DOI · Paper page
- Ruiz, 2012, Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells, Proc Natl Acad Sci U S A, 109, 16196, 10.1073/pnas.1202352109 · DOI · Paper page
- Pociot, 2016, Genetic risk factors for type 1 diabetes, Lancet, 387, 2331, 10.1016/S0140-6736(16)30582-7 · DOI · Paper page
- Pullen, 2018, Stem cell-derived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018, Am J Transplant, 18, 1581, 10.1111/ajt.14954 · DOI
- van der Torren, 2017, Immunogenicity of human embryonic stem cell-derived beta cells, Diabetologia, 60, 126, 10.1007/s00125-016-4125-y · DOI
- Szot, 2015, Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm, Cell Stem Cell, 16, 148, 10.1016/j.stem.2014.12.001 · DOI
- Joshi, 2021, Modeling type 1 diabetes using pluripotent stem cell technology, Front Endocrinol, 12, 10.3389/fendo.2021.635662 · DOI
- Marfil-Garza, 2020, Current state and evidence of cellular encapsulation strategies in type 1 diabetes, Compr Physiol, 10, 839, 10.1002/j.2040-4603.2020.tb00139.x · DOI
- Ernst, 2019, Nanotechnology in cell replacement therapies for type 1 diabetes, Adv Drug Deliv Rev, 139, 116, 10.1016/j.addr.2019.01.013 · DOI
- Ernst, 2018, Islet encapsulation, J Mater Chem B, 6, 6705, 10.1039/C8TB02020E · DOI
- Korsgren, 2017, Islet encapsulation: physiological possibilities and limitations, Diabetes, 66, 1748, 10.2337/db17-0065 · DOI
- Bhatt, 2012, Tolerance-inducing strategies in islet transplantation, Internet J Endocrinol, 10.1155/2012/396524 · DOI
- Marfil-Garza, 2021, Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation, Endocr Rev, 42, 198, 10.1210/endrev/bnaa028 · DOI
- Todo, 2016, A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation, Hepatology, 64, 632, 10.1002/hep.28459 · DOI · Paper page
- Sawitzki, 2020, Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials, Lancet, 395, 1627, 10.1016/S0140-6736(20)30167-7 · DOI · Paper page
- Harden, 2021, Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients, Am J Transplant, 21, 1603, 10.1111/ajt.16395 · DOI
- Ferreira, 2019, Next-generation regulatory T cell therapy, Nat Rev Drug Discov, 18, 749, 10.1038/s41573-019-0041-4 · DOI · Paper page
- Rodriguez-Barbosa, 2020, The role of TNFR2 and DR3 in the in vivo expansion of Tregs in T cell depleting transplantation regimens, Int J Mol Sci, 21, 10.3390/ijms21093347 · DOI
- Taylor, 2005, Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching, Lancet, 366, 2019, 10.1016/S0140-6736(05)67813-0 · DOI · Paper page
- Lanza, 2019, Engineering universal cells that evade immune detection, Nat Rev Immunol, 19, 723, 10.1038/s41577-019-0200-1 · DOI · Paper page
- Rong, 2014, An effective approach to prevent immune rejection of human ESC-derived allografts, Cell Stem Cell, 14, 121, 10.1016/j.stem.2013.11.014 · DOI · Paper page
- Shi, 2020, Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins, Stem Cell, 38, 1423, 10.1002/stem.3269 · DOI
- Petersdorf, 2004, HLA matching in allogeneic stem cell transplantation, Curr Opin Hematol, 11, 386, 10.1097/01.moh.0000143701.88042.d9 · DOI
- Zhang, 2016, The importance of non-HLA antibodies in transplantation, Nat Rev Nephrol, 12, 484, 10.1038/nrneph.2016.88 · DOI · Paper page
- Bruin, 2015, Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice, Stem Cell Rep, 5, 1081, 10.1016/j.stemcr.2015.10.013 · DOI
- Helman, 2021, A stem cell approach to cure type 1 diabetes, Cold Spring Harbor Perspect Biol, 13, 10.1101/cshperspect.a035741 · DOI
- Wang, 2009, Dependence of mouse embryonic stem cells on threonine catabolism, Science, 325, 435, 10.1126/science.1173288 · DOI · Paper page
- Shiraki, 2014, Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells, Cell Metabol, 19, 780, 10.1016/j.cmet.2014.03.017 · DOI · Paper page
- Nagashima, 2018, Selective elimination of human induced pluripotent stem cells using medium with high concentration of L-alanine, Sci Rep, 8, 10.1038/s41598-018-30936-2 · DOI
- Tateno, 2011, Glycome diagnosis of human induced pluripotent stem cells using lectin microarray, J Biol Chem, 286, 20345, 10.1074/jbc.M111.231274 · DOI · Paper page
- Tateno, 2015, Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein, Stem Cell Rep, 4, 811, 10.1016/j.stemcr.2015.02.016 · DOI
- Haramoto, 2020, A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin, Regen Ther, 14, 306, 10.1016/j.reth.2020.03.017 · DOI
- Kuang, 2017, Efficient, selective removal of human pluripotent stem cells via ecto-alkaline phosphatase-mediated aggregation of synthetic peptides, Cell Chem Biol, 24, 685, 10.1016/j.chembiol.2017.04.010 · DOI
- Li, 2020, Single-cell RNA-seq reveals that CD9 is a negative marker of glucose-responsive pancreatic β-like cells derived from human pluripotent stem cells, Stem Cell Rep, 15, 1111, 10.1016/j.stemcr.2020.09.009 · DOI
- Nostro, 2015, Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines, Stem Cell Rep, 4, 591, 10.1016/j.stemcr.2015.02.017 · DOI · Paper page
- Liu, 1997, Design of polydactyl zinc-finger proteins for unique addressing within complex genomes, Proc Natl Acad Sci U S A, 94, 5525, 10.1073/pnas.94.11.5525 · DOI · Paper page
- Sanjana, 2012, A transcription activator-like effector toolbox for genome engineering, Nat Protoc, 7, 171, 10.1038/nprot.2011.431 · DOI · Paper page
- Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
- Brookhouser, 2017, May I cut in? Gene editing approaches in human induced pluripotent stem cells, Cells, 6, 10.3390/cells6010005 · DOI
- Martin, 2020, Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards, Nat Commun, 11, 2713, 10.1038/s41467-020-16455-7 · DOI
- Kim, 2011, High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice, PLoS One, 6
- Martin, 2019, Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-cas9 RNP and AAV6 donor-mediated homologous recombination, Cell Stem Cell, 24, 821, 10.1016/j.stem.2019.04.001 · DOI · Paper page
- Yabe, 2017, Efficient generation of functional pancreatic β-cells from human induced pluripotent stem cells, J Diabetes, 9, 168, 10.1111/1753-0407.12400 · DOI
- Balboa, 2021, Functional, metabolic and transcriptional maturation of stem cell derived beta cells, bioRxiv
- Mfopou, 2010, Noggin, retinoids, and fibroblast growth factor regulate hepatic or pancreatic fate of human embryonic stem cells, Gastroenterology, 138, 10.1053/j.gastro.2010.02.056 · DOI · Paper page
- D'Amour, 2005, Efficient differentiation of human embryonic stem cells to definitive endoderm, Nat Biotechnol, 23, 1534, 10.1038/nbt1163 · DOI · Paper page
- Rukstalis, 2009, Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration, Islets, 1, 177, 10.4161/isl.1.3.9877 · DOI
- Aiello, 2014, Thyroid hormones promote endocrine differentiation at expenses of exocrine tissue, Exp Cell Res, 322, 236, 10.1016/j.yexcr.2014.01.030 · DOI
- Aguayo-Mazzucato, 2013, Thyroid hormone promotes postnatal rat pancreatic β-cell development and glucose-responsive insulin secretion through MAFA, Diabetes, 62, 1569, 10.2337/db12-0849 · DOI
- Kanak, 2014, Inflammatory response in islet transplantation, Internet J Endocrinol, 10.1155/2014/451035 · DOI
- Bellin, 2014, Defective glucagon secretion during hypoglycemia after intrahepatic but not nonhepatic islet autotransplantation, Am J Transplant, 14, 1880, 10.1111/ajt.12776 · DOI
- Gupta, 1997, The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined, Diabetes, 46, 28, 10.2337/diab.46.1.28 · DOI
- Addison, 2020, Considerations for an alternative site of islet cell transplantation, J Diabetes Sci Technol, 14, 338, 10.1177/1932296819868495 · DOI
- Pettis, 2019, Subcutaneous insulin administration: sufficient progress or ongoing need?, J Diabetes Sci Technol, 13, 3, 10.1177/1932296818817011 · DOI
- Fukuda, 2019, The intraperitoneal space is more favorable than the subcutaneous one for transplanting alginate fiber containing iPS-derived islet-like cells, Regen Ther, 11, 65, 10.1016/j.reth.2019.05.003 · DOI
Cited by
Dadheech, N., Bermúdez de León, M., Czarnecka, Z., Cuesta-Gomez, N., Jasra, I. T., Pawlick, R., Marfil-Garza, B., Sapkota, S., Verhoeff, K., Razavy, H., et al. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00409-y · Cited by 23
Self-citation
Metadata
- Authors
- Dadheech, N., Cuesta-Gomez, N., Jasra, I. T., Verhoeff, K., Garza, B. M., Mouhammed, O., & Shapiro, A. M. J.
- Venue
- Journal of Immunology and Regenerative Medicine
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 17
- Pages
- 100064
- ISSN
- 2468-4988
- Cited by
- 5
- References
- 25
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opportunities and impediments of human pluripotent stem cell-derived islets in the treatment of diabetes. https://app.cochat.ai/papers/10.1016/j.regen.2022.100064
- The paper
- Dadheech, N., Cuesta-Gomez, N., Jasra, I. T., Verhoeff, K., Garza, B. M., Mouhammed, O., & Shapiro, A. M. J. (2022). Opportunities and impediments of human pluripotent stem cell-derived islets in the treatment of diabetes. Journal of Immunology and Regenerative Medicine. https://doi.org/10.1016/j.regen.2022.100064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.